NEW YORK – ArteraAI and CorePlus on Thursday announced a research agreement focused on validating the ArteraAI Prostate Test in Hispanic patients.
San Francisco-based ArteraAI is developing artificial intelligence tests for personalizing cancer therapy. In May, the firm announced it had raised $90 million to commercialize an AI-based test that can identify which prostate cancer patients are at risk of disease progression and which patients might benefit from hormone therapy.
ArteraAI said in a statement that it is committed to training its AI models using diverse datasets. Roughly one-fifth of the patient data used in the initial training cohort for the ArteraAI multimodal artificial intelligence, or MMAI, prostate cancer models came from African Americans, according to the firm.
The latest collaboration will allow ArteraAI to validate its prostate cancer test's prognostic and predictive capabilities in Hispanic patients using data housed at Puerto Rico-based laboratory CorePlus.
"This research agreement provides a strong step forward in increasing understanding of differences and reducing disparities in access to precision diagnostics [and] creating more equitable and personalized care for prostate cancer patients," CorePlus CEO Mariano de Socarraz said in a statement.
The firms did not disclose the financial details of their collaboration.